Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Fortress Biotech, Inc. FBIOP
$18.66
+$0.04 (0.19%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
101506422.00000000
-
week52high
22.42
-
week52low
16.86
-
Revenue
75743000
-
P/E TTM
-14
-
Beta
1.98719700
-
EPS
-0.86300000
-
Last Dividend
2.34000000
-
Next Earnings Date
07 авг 2020 г. в 10:59
Описание компании
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Buy | Buy | 20 апр 2021 г. |
| Roth Capital | Buy | Buy | 13 окт 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 12 окт 2020 г. |
| Benchmark | Buy | 02 окт 2020 г. | |
| B. Riley FBR | Buy | Buy | 13 мар 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| ROSENWALD LINDSAY A MD | A | 12953882 | 1219294 | 01 янв 2023 г. |
| Lu Lucy | A | 121403 | 50000 | 01 янв 2023 г. |
| Harvey Jimmie | A | 950000 | 100000 | 01 янв 2023 г. |
| Hoenlein Malcolm | A | 535636 | 50000 | 01 янв 2023 г. |
| Klein Dov | A | 851015 | 100000 | 01 янв 2023 г. |
| LOBELL J JAY | A | 1336000 | 100000 | 01 янв 2023 г. |
| Lorenz Kevin | A | 314572 | 50000 | 01 янв 2023 г. |
| Rowinsky Eric K | A | 920000 | 100000 | 01 янв 2023 г. |
| WEISS MICHAEL S | A | 13554430 | 1219294 | 01 янв 2023 г. |
| Lu Lucy | A | 71403 | 30000 | 16 дек 2022 г. |
Новостная лента
Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript
Seeking Alpha
10 ноя 2022 г. в 22:42
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Co-Founder President and Chief Executive Officer Ernie De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel Srinivas Sidgiddi - Vice President of Clinical Development and Medical Affairs Conference Call Participants Scott Henry - ROTH Capital Partners Brandon Folkes - Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Journey Medical's Third Quarter 2022 Financial Results and Corporate Update Conference Call.
Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
09 авг 2022 г. в 21:05
Journey Medical Corporation (NASDAQ:FBIO ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Claude Maraoui - Co-Founder President and Chief Executive Officer Ernest De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel Dr. Srinivas Sidgiddi - Vice President of Clinical Development and Medical Affairs Conference Call Participants Brandon Folkes - Cantor Fitzgerald Mayank Mamtani - B. Riley FBR Operator Ladies and gentlemen, thank you for standing by.